Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Authors
Keywords
Adverse events, Cancer immunotherapy, Cancer treatment, Data management, Toxicity, T cells, Colitis, Drug administration
Journal
PLoS One
Volume 11, Issue 7, Pages e0160221
Publisher
Public Library of Science (PLoS)
Online
2016-07-30
DOI
10.1371/journal.pone.0160221
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Managing Adverse Events With Immune Checkpoint Agents
- (2016) Ramona Dadu et al. CANCER JOURNAL
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Immune checkpoint combinations from mouse to man
- (2015) Midan Ai et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inhibitory receptors as targets for cancer immunotherapy
- (2015) Meghan E. Turnis et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma
- (2015) Elnaz Faghfuri et al. Expert Review of Anticancer Therapy
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
- (2015) Matthew M. K. Chan et al. JOURNAL OF IMMUNOTHERAPY
- Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
- (2015) Mizuki Nishino et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
- (2015) J Gao et al. ONCOGENE
- Drug-Associated Dermatomyositis Following Ipilimumab Therapy
- (2015) Shirwa Sheik Ali et al. JAMA Dermatology
- Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
- (2014) D. Gardner et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
- (2014) Gary Hunter et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Drug-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA-4
- (2013) Barbara L. Goldstein et al. Arthritis & Rheumatology
- Primer on tumor immunology and cancer immunotherapy
- (2013) Timothy J Harris et al. Journal for ImmunoTherapy of Cancer
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
- (2011) Ahmad Tarhini et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More